-
Nucleic acid detection above the base air vent.
Time of Update: 2020-07-24
how to make use of the opportunity of this nucleic acid reagent heat, to promote their own strength, is the ultimate issue to consider. recently, after the outbreak of new areas, nucleic acid testing has once again become a hot topic
-
Immunity . . . The Whine group clarified the conjugate relationship between tumor immunotherapy targets.
Time of Update: 2020-07-23
8 While Repressing the Puty EIny And CTLA-4 Pathways" reveals an unexpected conjugate link between the PD-1 and CTLA-4 pathways, explaining why blocking both PD-L1 and CTLA-4 activates anti-tumor immunity in T cells.
-
Pneumonia vaccine! Mercado 15 price pneumococcal conjugate vaccine V114 two adult Phase III clinical studies were successful!
Time of Update: 2020-07-20
, June 23, 2020 // Biovalley BIOON/-- Merck and Co recently announced the results of two Phase III clinical studies evaluating the safety, tolerance, and immunogenicity of the 15-valent pneumococcal-combined vaccine V114, showing
-
cancer was reduced by 59%, and innovative antibody conjugate drugs reached stage 3 clinical endpoint.
Time of Update: 2020-07-18
▎ the drug Mingcond Content Team Editor Today, The Company's antibody conjugate drug Trodelvy (sacituzumab govitecan-hziyy), which has achieved the primary endpoint of progression-free survival (PFS) in the treatment of metastatic triple-negative
-
Express . . . Seek accelerated approval, innovative antibody conjugal drug treatment for cervical cancer Phase 2 clinical results are positive.
Time of Update: 2020-07-18
Seattle Genetics, editor of the ▎'s content team, has announced that it and Genmab have jointly developed an innovative antibody conjugate drug (ADC) tisotumab vedotin, which has obtained positive top-line results in a potentially registered Phase 2
-
Her2 plus breast cancer heavy new drug! AstraZeneca/I-Sanantibodies-Drug Conjugate Enhertu EU Entry Review, Total Mitigation Rate 60.3%
Time of Update: 2020-07-15
Can, DS-8201) Marketing Authorization Application (MAA), a target ingenuated with HER2 antibody drug conjugate (ADC), is used to treat patients with non-removable or metastatic HER2-positive breast cancer who have previously received at least 2 anti-HER2 treatment regimens.
-
TNBC's new drug! The first TROP-2 target antibody-drug conjugate Trodelvy III phase: significantly extended survival!
Time of Update: 2020-07-15
April, the company's first commercial ADC product, Trodelvy (sacituzumab govitecan-hziy), received accelerated FDA approval for metastatic triple-negative breast cancer (mTNBC) adult patients who had previously received at least two treatments for metastatic disease.
-
Antibody drug conjugate DS-1062 study expanded to treat triple-negative breast cancer patients
Time of Update: 2020-07-14
The First Three announced that its antibody drug Couple (ADC), which targets TROP2, is being evaluated for safety, tolerance and initial efficacy in patients with advanced non-removable or metastatic three-negative breast cancer (TNBC).
-
Reduces risk of death by 59% antibody conjugate drug Trodelvy Breast Cancer Phase 3 Clinical End
Time of Update: 2020-07-12
. Retrieved July 6, 2020, from Original Title: Reducing disease progression risk in patients with triple-negative breast cancer 59%, innovative antibody conjugate drugs reach phase 3 clinical endpoint
-
Hubei and Shanghai will form amino acid production bases
Time of Update: 2020-07-03
Hubei and Shanghai will soon form the two major amino acid production bases, Jilin Province will form a new amino acid production base in Northeast China, Anlitai Pharmaceutical Co., Ltd. will become the largest amino acid production base
-
High purity amino acid industry base project started
Time of Update: 2020-07-03
high-purity amino acid industry base project started Wang Wei and other attended the ceremony This morning, Changchun Economic and Technological Development Zone corn industrial park a festive atmosphere.
-
Changchun Economic and Technological Development Zone Amino Acid Base for the second batch
Time of Update: 2020-07-02
December 26, 2012, the Ministry of Commerce officially recognized the amino acid base of Changchun Economic and Technological Development Zone as the second batch of national foreign trade transformation and upgrading professional
-
Yichang builds central drug valley Three Gorges pharmaceutical amino acid industry base put into production
Time of Update: 2020-06-30
g9F g9F on the morning of January 16, Yichang Three Gorges Pharmaceutical Co., Ltd. amino acid industry base in Yichang High-tech Zone Bioindustrial Park officially put into operation.
-
EHA 2020: New anti-cancer peptide-drug conjugate Melflufen treatment of refractive multiple myeloma, Phase 2 HORIZON trial successful
Time of Update: 2020-06-25
HORIZON studies have shown that Melflufen, which is associated with dexamethasone, may provide new treatment options for patients with RRMM who are difficult to treat and have poor prognosis, including tertiary refractive myeloma.
-
Tianyan Pharmaceutical and Tanabe Research Laboratory have reached a cooperation to help develop new antibody conjugate drugs
Time of Update: 2020-06-16
TRL will develop a new generation of antibody conjugate drugs (ADCs) for solid tumor targets using safEbody ® (Safe Antibody Platform), a proprietary antibody masking technology developed by Tianyin Pharmaceuticals.
-
Tianyan Pharmaceutical and Tanabe Research Laboratory have reached a cooperation to help develop new antibody conjugate drugs
Time of Update: 2020-06-16
TRL will develop a new generation of antibody conjugate drugs (ADCs) for solid tumor targets using safEbody ® (Safe Antibody Platform), a proprietary antibody masking technology developed by Tianyin Pharmaceuticals.
-
Antibody drug conjugate ILUMYA (tildrakizumab-asmn) treatment of moderate-severe plaqueized psoriasis: good long-term safety effectiveness
Time of Update: 2020-06-16
An after-the-fact analysis of 335 patients with moderate to severe plaque psoriasis found that patients who reached PASI 50 or higher after 6 months of iLUMYA treatment continued to improve and their response rate increased for up to three years.
-
FDA approves gene tektronix antibody conjugate drug Polivy for treatment of incurable diffuse large B-cell lymphoma in adult patients
Time of Update: 2020-06-09
today, the United States The FDA ( announced the accelerated approval of gene tektronix's antibody conjugate drug ( Polatuzumab vedotin-piiq
-
Mercado15 pneumococcal conjugate vaccine V114 reaches major endpoint in Phase 2 clinical trial
Time of Update: 2020-06-09
in infants with healthy ( at 6-12 weeks, the prevention of 13 serotypes covered by the two vaccines met the non-adverse standard compared to the existing 13-price pneumococcal conjugate vaccine (PCV13).
-
AbbVie antibody drug conjugated Rova-T treatment of small cell lung cancer stage III clinical failure
Time of Update: 2020-06-08
Based on a pre-planned interim analysis, the Independent Data Monitoring Committee (IDMC) recommended that the MERU study be discontinued because patients receiving Rova-T treatment had no survival benefits compared to the placebo control group
